APPENDIX B PENDING CLAIMS

	l antibody and a complementarity-determining region (CDR) that recognizes a		
metal chelate or portions thereof, wherein said reactive site is in a position proximate to or within			
said complementarity-determining region.			
2.	The mutant antibody according to claim 1, wherein said reactive site is a side-		
	occurring or non-naturally occurring amino acid.		
Chain of a naturally	deciming of non-naturally cools and a second		
3.	The mutant antibody according to claim 2, wherein said reactive site is the		
-SH group of cystei	ne.		
10.	(Once amended) A polypeptide comprising a peptide sequence according to		
SEQ. ID NO.:5 (FIG	G. 12).		
11.	A polypeptide comprising a peptide sequence according to SEQ. ID NO.: 7		
(FIG. 14).			
(113.11).			
14.	(Once amended) The mutant antibody according to claim 1, wherein said		
mutant antibody is a mutant of CHA255.			
15	The mutant antibody according to claim 14, wherein serine-95 of the light-		
•			
2 chain is substituted by a cysteine residue.			
16.	The mutant antibody according to claim 1, wherein said antibody is a		
bifunctional antibod	y further comprising a second complementarity-determining region that		
specifically binds to	a cell-surface antigen.		
•			
17.	The mutant antibody according to claim 1, further comprising a targeting		
moiety covalently at	tached thereto.		
18.	The mutant antibody according to claim 17, having the structure:		
	Ab-L-T		
wherein,			
	epresents said antibody;		
	16. bifunctional antibod specifically binds to 17. moiety covalently at 18. wherein,		

5	L is a chemical bond or linking group; and		
6	T is said targeting moiety.		
1	19. The mutant antibody according to claim 17, wherein said targeting moiety is		
2	an antibody that binds specifically to a cell surface antigen.		
1	20. The mutant antibody according to claim 1, further comprising said metal		
2	chelate bound to said complementarity-determining region, wherein said chelate comprises a		
3	reactive functional group of complementary reactivity to said reactive site of said antibody.		
1	21. (Once amended) The mutant antibody according to claim 20, further		
2	comprising a covalent bond formed by reaction of said reactive site of said antibody and said		
3	reactive functional group of said chelate.		
1	22. The mutant antibody according to claim 20, wherein said reactive site of said		
2	chelate is an acrylamido moiety.		
1	23. The mutant antibody according to claim 1, wherein said metal chelate is a		
2	polyaminocarboxylate chelate of a metal ion selected from the group consisting of transition metal		
3	ions and lanthanide ions.		
1	24. A pharmaceutical composition comprising the mutant antibody according to		
2	claim 17, and a pharmaceutically acceptable carrier.		
1	25. (Twice amended) A mutant antibody comprising a cysteine residue not		
2	present in the wild-type of said antibody and a complementarity-determining region that recognizes		
3	a metal chelate or portions thereof, wherein said cysteine is in a position proximate to or within said		
4	complementarity-determining region.		
1	30. The antibody according to claim 25, wherein said antibody is a bifunctional		
2	antibody further comprising a second complementarity-determining region that specifically binds to		
3	a cell-surface antigen.		
1	31. The mutant antibody according to claim 25, further comprising a targeting		
2	moiety covalently attached thereto.		

l	32. The mutant antibody according to claim 31, having the structure:		
2.	Ab-L-T		
3	wherein,		
1	Ab represents said antibody;		
5	L is a chemical bond or linking group that may contain one or more functional		
5	groups; and		
7	T is said targeting moiety		
l	33. The mutant antibody according to claim 31, wherein said targeting moiety is a		
2	member selected from the group consisting of antibodies and antibody fragments, each of which		
3	bind specifically to a cell surface antigen.		
l	34. The mutant antibody according to claim 25, further comprising said metal		
2	chelate bound to said complementarity-determining region, wherein said chelate comprises a		
3	reactive functional group of complementary reactivity to the -SH side-chain of said cysteine		
4	residue.		

1	35.	The mutant antibody according to claim 34, further comprising a covalent	
2`	bond formed by reaction of the -SH side-chain of cysteine and said reactive functional group of said		
3	chelate.		
1	36.	The mutant antibody according to claim 35, wherein said reactive functional	
2		is an acrylamido moiety.	
_	group of oura energies		
1	37.	The mutant antibody according to claim 25, wherein said metal chelate is a	
2	polyaminocarboxylate chelate of a metal ion selected from the group consisting of transition metal		
3	ions and lanthanide ions.		
_	••	A 1	
1	38.	A pharmaceutical composition comprising the mutant antibody according to	
2	claim 31, and a pharmaceutically acceptable carrier.		
1	42.	(New) A mutant antibody comprising a reactive site not present in the wild-	
2	type of said antibody and a complementarity-determining region (CDR) that specifically binds a		
3	metal chelate, wherein said reactive site is in a position proximate to or within said complementarity-		
4	determining region.		
1	43.	(New) A mutant antibody comprising a reactive site not present in the wild-	
2	type of said antibody	and a complementarity-determining region (CDR) that recognizes a metal	
3	chelate comprising a reactive group or portions thereof, wherein said reactive site is in a position		
4	proximate to or within said complementarity-determining region, and		
5	wherein said reactive group has complementary reactivity to said reactive site of said		
6	antibody.		
9	J.		

SF 1377851 V2